Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality

MLA

Elizabeth D. Williams, et al. “Neuropilin-1 Is Upregulated in the Adaptive Response of Prostate Tumors to Androgen-Targeted Therapies and Is Prognostic of Metastatic Progression and Patient Mortality.” Oncogene, vol. 36, Jan. 2017, pp. 3417–27. EBSCOhost, https://doi.org/10.1038/onc.2016.482.

APA

Elizabeth D. Williams, K McGowan, Miriam S. Butler, Jennifer H. Gunter, Ellca Ratther, Pamela J. Russell, N. Erho, Mohammed Alshalafa, Melanie Lehman, Mannan Nouri, Edward M. Schaeffer, Ladan Fazli, Robert Jeffrey Karnes, P S Rennie, Ashley E. Ross, Brett G. Hollier, Stephen McPherson, Nataly Stylianou, Rajdeep Das, … Cheryl Y. Gregory-Evans. (2017). Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene, 36, 3417–3427. https://doi.org/10.1038/onc.2016.482

Chicago

Elizabeth D. Williams, K McGowan, Miriam S. Butler, Jennifer H. Gunter, Ellca Ratther, Pamela J. Russell, N. Erho, et al. 2017. “Neuropilin-1 Is Upregulated in the Adaptive Response of Prostate Tumors to Androgen-Targeted Therapies and Is Prognostic of Metastatic Progression and Patient Mortality.” Oncogene 36 (January): 3417–27. doi:10.1038/onc.2016.482.